Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017043 · ClinicalTrials.gov registry record · Phase 2
BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy
A Phase 2 study of Gastric Cancer and Esophageal Cancer, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00017043: Completed Phase 2 study of Gastric Cancer and Esophageal Cancer, sponsored by Bristol-Myers Squibb.
NCT00017043 is a Phase 2 study of Gastric Cancer and Esophageal Cancer that has completed, run by Bristol-Myers Squibb. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00017043, a Phase 2 study of Gastric Cancer and Esophageal Cancer, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have metastatic stomach cancer previously treated with chemotherapy.
Conditions Studied
Interventions
- DRUG ixabepilone
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-02 |
| Est. Completion | 2003-01 |
| Phase | Phase 2 |
What the finished NCT00017043 record still lists
NCT00017043 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which ixabepilone is the first listed.
NCT00017043 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00017043 about?
NCT00017043 is a clinical study titled "BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have metastatic stomach cancer previously treated with chemotherapy.
What is the current status of trial NCT00017043?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-02. Estimated completion is 2003-01.
What conditions does trial NCT00017043 study?
This clinical trial studies the following conditions: Gastric Cancer, Esophageal Cancer.
What interventions are being tested in trial NCT00017043?
The interventions under investigation include: ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00017043?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00017043 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia